Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: A systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 76, Issue 6, 2017, Pages 1102-1107

  Chatzidionysiou, Katerina ^a   Emamikia, Sharzad ^a   Nam, Jackie ^b   Ramiro, Sofia ^c   Smolen, Josef ^d   Van Der Heijde, Désirée ^c   Dougados, Maxime ^e   Bijlsma, Johannes ^f   Burmester, Gerd ^g   Scholte, Marieke ^h,i   Van Vollenhoven, Ronald ^a,j   Landewé, Robert ^j  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY OF TWENTE   (Netherlands)

ⁱ EULAR Standing Committee of People with Arthritis Rheumatism in Europe   (Netherlands)

^j Amsterdam Rheumatology and Immunology Center   (Netherlands)

more..

Author keywords

Corticosteroids; DMARDs (synthetic); Rheumatoid Arthritis; Treatment

Indexed keywords

ADALIMUMAB; AURANOFIN; AZATHIOPRINE; BARICITINIB; C REACTIVE PROTEIN; CHLORAMBUCIL; COLLOIDAL GOLD; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID; PENICILLAMINE; PLACEBO; SALAZOSULFAPYRIDINE; TACROLIMUS; TOFACITINIB; TRIAMCINOLONE; ANTIRHEUMATIC AGENT; AZETIDINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ARTICLE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZETIDINES; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; METHOTREXATE; PIPERIDINES; PRACTICE GUIDELINES AS TOPIC; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES;

EID: 85019190499     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210711     Document Type: Article

References (37)

1. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
2. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs-2016 update. Ann Rheum Dis 2013; , submitted 2016.
3. Gaujoux-Viala C, Nam J, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: A systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:510-15.
4. Nam J, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological DMARDs-A systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2016; , submitted.
5. Ramiro S, Gaujoux-Viala C, Nam J, et al. Safety of synthetic and biological DMARDs-A systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis , Submitted 2016.
6. Menon N, Kothari SY, Gogna A, et al. Comparison of intra-Articular glucocorticoid injections with DMARDs versus DMARDs alone in rheumatoid arthritis. J Assoc Physicians India 2014;62:673-6.
7. Verschueren P, De Cock D, Corluy L, et al. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther 2015;17:97.
8. den Uyl D, ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated combination strategy (COBRA-light) compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 2014;73:1071-8.
9. ter Wee MM, den Uyl D, Boers M, et al. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis 2015;74:1233-40.
10. Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013;72:204-10.
11. de Jong PH, Hazes JM, Barendregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 2013;72:72-8.
12. de Jong PH, Hazes JM, Han HK, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis 2014;73:1331-9.
13. Verschueren P, De Cock D, Corluy L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-To-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: The CareRA trial. Ann Rheum Dis 2015;74:27-34.
14. Dhir V, Singla M, Gupta N, et al. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis. Clin Ther 2014;36:1005-15.
15. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: The randomised CONCERTO trial. Ann Rheum Dis 2015;74:1037-44.
16. Cutolo M, Bolosiu H, Perdriset G. Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen. Rheumatology 2013;52:1132-40.
17. Ren LM, Li R, Chen LN, et al. Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: A randomized, multi-center study. Int J Rheum Dis 2016;19:651-7.
18. Strand V, Kremer J, Wallenstein G, et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther 2015;17:307.
19. Strand V, Burmester GR, Zerbini CA, et al. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial. Arthritis Care Res (Hoboken) 2015;67:475-83.
20. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70.
21. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet 2013;381:451-60.
22. Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis a randomized trial. Annals of Internal Medicine 2013;159:253-61.
23. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-86.
24. Tanaka Y, Takeuchi T, Yamanaka H, et al. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: A 12-week, randomized, phase 2 study. Mod Rheumatol 2015;25:514-21.
25. Wallenstein GV, Kanik KS, Wilkinson B, et al. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clin Exp Rheumatol 2016;34:430-42.
26. Strand V, van Vollenhoven RF, Lee EB, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology 2016;55:1031-41.
27. Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015;74:333-40.
28. Tanaka Y, Emoto K, Cai Z, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: A 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 2016;43:504-11.
29. Fleischmann R, Takeuchi T, Schlichting DE, et al. Baricitinib, Methotrexate, or Baricitinib Plus Methotrexate in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Phase 3 Trial Results. Arthritis Rheumatol 2015;67:506-17.
30. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study. Ann Rheum Dis 2015;67:14-16.
31. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016;374:1243-52.
32. Emery P, Gaich CL, DeLozier AM, et al. Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. Arthritis Rheumatol 2015;67.
33. Smolen JS, Kremer J, Gaich C, et al. Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Tumor Necrosis Factor Inhibitor. Ann Rheum Dis 2015;74(Suppl 2):785-6.
34. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88-95.
35. de Hair M, Ijff N, Jacobs J, et al. Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II. Arthritis Rheumatol 2015;67.
36. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560-7.
37. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: A systematic review of the literature. Ann Rheum Dis 2009;68:1094-9.